Six Top Stories From the EULAR Annual Congress

Issue: July 2017

Healio Rheumatology features the top stories from EULAR Annual Congress. More of Healio Rheumatology’s live coverage, including video interviews with researchers, can be found by clicking here.

Long-term hydroxychloroquine therapy may reduce cardiovascular events in SLE

MADRID — Long-term use of hydroxychloroquine was associated with reduced cardiovascular risks in a cohort of patients with systemic lupus erythematosus, according to findings presented at the EULAR Annual Congress. Read More.

History of nontuberculous mycobacteria infection linked to incident Sjögren’s syndrome

MADRID — Recent diagnosis with Sjögren’s syndrome appears to be significantly linked to a history of nontuberculous mycobacteria infection, according to findings presented here. Read More.

Early intervention may reduce onset of RA

MADRID — Early therapeutic intervention for patients with pre-rheumatoid arthritis may significantly reduce the odds for full onset of the disease, according to findings from a meta-analysis presented at the Annual European Congress of Rheumatology. Read More.

Study finds three knee pain subgroups of osteoarthritis

MADRID — A 10-year investigation of knee pain in osteoarthritis revealed three general pain subgroups, suggesting the individualized process of pain may be categorized, according to findings presented here. Read More.

Study finds FKB327 non-inferior to adalimumab regarding pharmacokinetics, safety

MADRID — A novel candidate biosimilar to adalimumab known as FKB327 demonstrated non-inferiority for efficacy and safety outcomes compared with the reference therapy, according to findings. Read More.

Tofacitinib reached musculoskeletal safety endpoints in PsA

MADRID — Two different dosing levels of tofacitinib bested placebo in response rate and safety parameters for patients with psoriatic arthritis, according to findings presented at the EULAR Annual Congress. Read More.